
What smart money is saying about RxSight
1 fund in our archive has pitched RxSight — most recently Artisan Non US Small Mid Growth Strategy in June 2025.
RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
Get an email when a fund writes about it
Fund coverage · 1 thesis
- Artisan Non US Small Mid Growth StrategyJune 2025
RxSight is a company with innovative adjustable intraocular lens technology that has faced recent challenges but is expected to demonstrate long-term value.
Read the full thesis
Read every full thesis on RxSight
Unlock all 1 thesis — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→